PT-141 (Bremelanotide): The Complete Research Guide for 2026

PT-141 is one of the more interesting compounds in the research peptide space because it's actually FDA-approved (as Vyleesi, by Palatin Technologies). The approved indication is hypoactive sexual desire disorder in premenopausal women, but the off-label research and community use extends to men and to general libido enhancement.

This guide covers what PT-141 actually does, what the published evidence shows, the side-effect profile, dosing patterns researchers use, and how to compare current vendor pricing.

You can also see live PT-141 vendor pricing across our 31 tracked vendors at any time.

What Is PT-141?

PT-141 (also called bremelanotide) is a synthetic peptide derived from melanotan II. The "PT" stands for "PalaTin," the company that developed it. Unlike the parent compound melanotan II, PT-141 was specifically engineered to remove the skin-tanning effects while preserving the sexual-arousal effects.

It works through a completely different mechanism than the better-known erectile dysfunction drugs (sildenafil/Viagra, tadalafil/Cialis):

PDE5 inhibitors (Viagra/Cialis) work peripherally — they enhance the blood-flow response when arousal signals reach the genitals
PT-141 works centrally — it activates melanocortin receptors in the brain, generating arousal signals at the source

This difference matters. PDE5 inhibitors require the user to already be aroused. PT-141 generates the arousal itself, which is why it works for users who don't respond to PDE5 inhibitors and for women, whose arousal physiology is less amenable to peripheral blood-flow drugs.

What Does the Research Actually Show?

The clinical evidence base for PT-141 is unusually robust for a research peptide.

RECONNECT trials (women): Two Phase 3 trials in premenopausal women with HSDD enrolled ~1,250 participants total. Results showed statistically significant improvements in desire and reduced distress vs placebo. These data drove the 2019 FDA approval as Vyleesi.

Earlier Phase 2 work in men: Studies in men with erectile dysfunction (including some who didn't respond to sildenafil) showed efficacy on the order of 60-70% reporting improved function vs ~25% placebo. The compound was originally developed for ED but was reformulated and re-targeted for women due to development considerations.

Off-label community data: Community reports for general libido enhancement (in men, women, and couples without diagnosed dysfunction) are largely positive but lack rigorous trial support.

Side Effects: The Real Story

Here's where PT-141 gets honest. The side-effect profile is significant — significantly worse than most peptides on the market — and anyone considering use should understand this upfront.

Nausea is the headline side effect. In the RECONNECT trials, 40% of women reported nausea on standard 1.75mg dose. About 13% reported it severe enough to discontinue. Most users find it improves over the first 1-3 doses but doesn't disappear.

Other documented effects:

Flushing / hot flashes — common, mild, usually 30-60 min post-dose
Headache — common
Mole / skin darkening — uncommon but documented; melanocortin activation can darken existing pigmentation. Usually reverses over weeks-months after discontinuation
Blood pressure increase — typically transient ~6mmHg systolic, usually clinically insignificant but contraindicated in poorly-controlled hypertension
Decreased appetite — sometimes reported
Yawning (no, really) — documented in research, mechanism unclear

The trade-off most users describe: significant nausea for 1-2 hours in exchange for several hours of improved libido. Whether that's worth it depends on the individual.

Dosing Patterns

Important: dosing protocols below are documented patterns from published research and case reports. They are not medical recommendations.

Approved Vyleesi protocol (women, HSDD):

1.75mg SC, used as-needed
At least 45 minutes before anticipated activity
No more than once per 24 hours
No more than 8 doses per month

Common research/off-label protocols (men, general use):

1.0-2.0mg SC as-needed, 30-60 min before activity
Some users start at 0.5mg to test tolerability before scaling up
Many find lower doses (0.5-1.0mg) sufficient with markedly fewer side effects

Combination patterns:

Some research and community reports describe combining PT-141 with Oxytocin (intranasal, 10-20 IU) for additional emotional/bonding effects
Not combined with sildenafil or tadalafil in published research due to blood-pressure interaction concerns

Vyleesi (Pharmacy) vs Research-Grade PT-141

Two paths to access the same compound, with different trade-offs.

Vyleesi (pharmacy):

FDA-approved; prescription required
~$95-150 per single-use auto-injector
Quality controlled by pharmaceutical manufacturer
Insurance coverage limited

Research-grade PT-141:

Vials of lyophilized peptide, reconstitute with bacteriostatic water
~$30-60 per 10mg vial (5-10 doses depending on protocol)
Vendor-dependent quality
Requires syringes, BAC water, basic injection knowledge

For someone using PT-141 frequently, research-grade represents a 5-10x cost reduction. For occasional use, Vyleesi's convenience may justify the premium. The research-grade route requires careful vendor selection because compound identity matters more here than for some compounds — wrong-product or under-dosed PT-141 doesn't just produce a weaker effect; it can produce no effect at all and waste the time investment of a planned occasion.

Cheapest PT-141 vendors.

Vendor Verification for PT-141

Standard checks apply, with one specific addition:

Public, named-lab COA (Janoshik, Colmaric, MZ Biolabs)
Compound identity confirmation — mass spec showing the correct molecular weight (1024.18 g/mol for PT-141 acetate)
Purity ≥98% by HPLC
Recent batch testing — within the last 6 months ideally
Trustpilot reviews mentioning PT-141 specifically — purity issues with this specific compound do come up; review history matters

Vendors we currently rate well for PT-141 specifically: Modern Aminos, Ascension Peptides, LeoLab Rx, SomaChems. See our vendor list for full ratings or the is-legit pages for individual vendor breakdowns.

Common Questions

Does PT-141 work for women?
Yes — that's the FDA-approved indication. The strongest published data is in premenopausal women with diagnosed HSDD.

Does PT-141 work for men?
Yes, based on Phase 2 trials and substantial community data. Most users report effects within 1-2 hours of injection lasting 4-8 hours.

How is PT-141 different from Viagra?
Viagra (sildenafil) works peripherally on blood flow and requires existing arousal. PT-141 works centrally on the brain to generate arousal. Different mechanism, different best-fit cases. Some users respond to one but not the other.

Can PT-141 be combined with Viagra?
Not in published research. There are theoretical blood-pressure interaction concerns. Discuss with a physician before combining.

Is PT-141 safe long-term?
Acute safety is well-established for occasional use. Chronic daily use is not well-studied. The approved Vyleesi protocol limits to 8 doses/month for safety reasons.

Does PT-141 cause skin tanning?
Less than melanotan II (the parent compound), but still possible. Mole darkening is the most-reported pigmentation effect. Usually mild and reversible.

Bottom Line

PT-141 is one of the more interesting peptides on the market because the evidence base is unusually strong (FDA-approved, with published Phase 3 data) and the mechanism is genuinely different from existing alternatives.

The honest assessment:

It works for many people who don't respond to PDE5 inhibitors
The side effects are real and significant — nausea especially
Vendor verification is critical because compound identity matters more here than for many peptides
Cost arbitrage between Vyleesi and research-grade is substantial for frequent users

If you're considering PT-141:

Research the side-effect profile honestly. Plan for nausea on the first 1-2 doses
Start at a lower dose (0.5-1.0mg) to test tolerability
Verify your vendor — see our methodology and the PT-141 vendor list
Don't combine with PDE5 inhibitors without medical guidance

When you're ready to compare current pricing:

For research use only. Not medical advice. Always consult a qualified healthcare provider before working with any research compound.